Replies to post #208168 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

beachhyena,

Agreed that November could have been the beginning of the process of PFS adjudication which adds some time before data lock. This gives OS more time to mature to the point where OS eventing apparently nearly flat lines which is actually after the 36 month mark based on the curves. February marks a minimum 42 months post surgery for all patients which gives time for data lock to be announced by March. This is the time that the financing points to as being important. None of this means anything unless the company itself confirms a potential projected time line but at least there are some consequences in place for NWBO failure to be timely with news. I expect the ASM to be a clear move in the right direction. Best wishes.

[exwannabe]

I am with Smith and scrub starting November.

Smith said on Oct 11:

New data on the phase 3 trial will likely come in the form of another look at the blinded data as was done before. I think that this will be a dramatic event and it could come in the time that I am not around. The Company has been working on this for some time and in the process is scrubbing the data from the various sites, which will be necessary for the regulatory submission.

SoS asserted as a fact that the scrub started well prior to Oct., not that it would start in Nov.